Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
McKinsey
Teva
Julphar
US Department of Justice
Covington
AstraZeneca
Argus Health

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEFERASIROX

« Back to Dashboard

Clinical Trials for Deferasirox

Trial ID Title Status Sponsor Phase Summary
NCT00061750 Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions Completed Novartis Pharmaceuticals Phase 3 The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
NCT00061763 Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias Completed Novartis Pharmaceuticals Phase 2 The purpose of this study is to determine the effects of the oral iron chelator Deferasirox on liver iron content after one year of treatment in patients with iron overload from repeated blood transfusions. Beta-thalassemia patients unable to be treated with deferoxamine or patients with rare chronic anemias such as Myelodysplastic Syndrome, Fanconi's Syndrome, Blackfan-Diamond Syndrome, and Pure Red Blood Cell Anemia are eligible for this study. Liver iron content will be measured by liver biopsy at the beginning of the study and after one year of treatment. However, those patients living in the San Francisco/Oakland area may have a SQUID in place of the liver biopsy if the biopsy is not medically possible for them. The SQUID is a non-invasive magnetic means to measure liver iron content.
NCT00067080 Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions Completed Novartis Pharmaceuticals Phase 2 The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
NCT00110266 Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients Completed Novartis Pharmaceuticals Phase 2 The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
NCT00110617 Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Completed Novartis Pharmaceuticals Phase 2 This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
NCT00117507 Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Completed Novartis Pharmaceuticals Phase 2 Thirty patients will be enrolled into this open-label, single-arm trial designed to assess the safety and tolerability of oral deferasirox in adult transfusion dependent myelodysplastic syndrome (MDS) patients with iron overload. Patients enrolled in this study will have low or intermediate (INT-1) risk MDS per International Prognostic Scoring System (IPSS) criteria. All patients will initiate treatment with 20mg/kg/day deferasirox. Deferasirox will be administered orally once per day for 12 months.
NCT00171171 A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Completed Novartis Phase 3 Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions. This study will evaluate the efficacy, safety and tolerability of deferasirox.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Deferasirox

Condition Name

Condition Name for Deferasirox
Intervention Trials
Iron Overload 15
Myelodysplastic Syndromes 11
Beta-thalassemia 7
Transfusional Iron Overload 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Deferasirox
Intervention Trials
Iron Overload 48
Thalassemia 32
Preleukemia 23
Myelodysplastic Syndromes 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Deferasirox

Trials by Country

Trials by Country for Deferasirox
Location Trials
United States 204
Italy 57
Canada 21
China 19
United Kingdom 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Deferasirox
Location Trials
California 22
New York 17
Illinois 15
Pennsylvania 14
Texas 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Deferasirox

Clinical Trial Phase

Clinical Trial Phase for Deferasirox
Clinical Trial Phase Trials
Phase 4 20
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 54
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Deferasirox
Clinical Trial Phase Trials
Completed 52
Recruiting 11
Unknown status 6
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Deferasirox

Sponsor Name

Sponsor Name for Deferasirox
Sponsor Trials
Novartis Pharmaceuticals 48
Novartis 10
Ann & Robert H Lurie Children's Hospital of Chicago 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Deferasirox
Sponsor Trials
Other 69
Industry 63
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Queensland Health
Colorcon
Fuji
Daiichi Sankyo
Accenture
Harvard Business School
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.